Clostridium Difficile Infection: Clinical Trials

19 completed, 8 terminated, 2 recruiting, 2 unknown. 33 Phase 2, 5 Phase 3, 4 Phase 1.

By phase and status

Phase	Trials	Status
Phase 2	33	Completed 19, Terminated 8, Recruiting 2, Unknown 2, Withdrawn 2
Phase 3	5	Terminated 3, Recruiting 1, Unknown 1
Phase 1	4	Completed 2, Terminated 2

Follow Clostridium Difficile Infection: new trials by email Literature Review of Clostridium Difficile Infection trials Research Report on Clostridium Difficile Infection

Trials (filtered) newest first · largest first

All 33 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Enteral Vancomycin as Primary Prophylaxis Against Clostridioides Difficile Infection in Critically Ill Patients Vancomycin 125mg, Placebo - Clostridium Difficile Infection, Vancomycin Resistant Enterococci Infection	Phase 2 / Phase 3	Recruiting	Riverside University Health System Medical Center	176	2024-10-21	2025-11-10
Phase II Trial of Fecal Microbiota Transplant (FMT) for VRE and CRE Patients FMT Capsule DE, Placebo oral capsule - Clostridium Difficile Infection	Phase 2	Withdrawn	University of Wisconsin, Madison		2022-09-01	2021-02-23
Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT) Alanyl-glutamine - Clostridioides Difficile Infection, Clostridium Difficile Infection	Phase 2	Recruiting	University of Virginia	260	2021-06-01	2024-10-26
ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection Ibezapolstat, Vancomycin - Clostridium Difficile Infection	Phase 2	Completed	Acurx Pharmaceuticals Inc.	53	2020-03-06	2025-01-17
ICON-2: FMT and Bezlotoxumab Compared to FMT and Placebo for Patients With IBD and CDI Bezlotoxumab, Placebo, Fecal Microbiota Transplantation - Inflammatory Bowel Diseases, Clostridium Difficile Infection	Phase 2	Completed	Brigham and Women's Hospital	61	2020-01-01	2025-12-09
Fecal Microbiota Transplant for Primary CDI Fecal microbiota transplant G3 capsules, Oral Vancomycin alone - Clostridium Difficile Infection	Phase 1 / Phase 2	Terminated	Boston Medical Center	5	2019-08-23	2021-12-15
The GRAFT Study: Gut RecolonizAtion by Fecal Transplantation Low Dose FMT Capsule DE, Single Dose FMT Capsule DE, Placebo oral capsule - Clostridium Difficile Infection, C.Difficile Diarrhea	Phase 2	Completed	University of Wisconsin, Madison	1	2019-03-21	2021-03-15
Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection VE303, Placebo - Clostridium Difficile Infection Recurrence, Clostridium Difficile Infection	Phase 2	Completed	Vedanta Biosciences, Inc.	79	2019-02-08	2023-07-03
Study to Assess Safety, Tolerability and Efficacy of Incremental Doses of MGB-BP-3 in Patients With CDAD MGB-BP-3 - Clostridium Difficile Infection	Phase 2	Completed	MGB Biopharma Limited	34	2019-02-07	2020-04-15
Microbiota or Placebo After Antimicrobial Therapy for Recurrent C. Difficile at Home (MATCH) Fecal Microbiota Therapy (FMT), Placebo - Clostridium Difficile Infection	Phase 2 / Phase 3	Terminated	VA Office of Research and Development	153	2018-11-15	2024-04-11
Vancomycin for C Difficile NAAT+/EIA- Hematology Oncology Patients Vancomycin Oral Capsule, Placebo Oral Capsule - Clostridium Difficile Infection, Hematologic Diseases	Phase 2	Completed	Medical College of Wisconsin	9	2018-06-01	2026-04-15
Efficacy of Oral Vancomycin Prophylaxis for Prevention of Recurrent Clostridium Difficile Infection Vancomycin, Placebo - Recurrent Clostridium Difficile Infection, Clostridium Difficile Infection	Phase 2	Completed	University of Wisconsin, Madison	79	2018-05-21	2025-05-25
Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection CP101 - Clostridium Difficile Infection, Recurrent Clostridium Difficile Infection	Phase 2	Completed	Finch Research and Development LLC.	132	2018-05-01	2022-08-30
Treatment for Clostridium-difficile Infection With IMM529 IMM-529, Placebo - Clostridium Difficile Infection, Clostridium Difficile Infection Recurrence	Phase 1 / Phase 2	Terminated	Immuron Ltd.	9	2017-09-01	2019-12-26
The ICON Study: Outcomes After FMT for Patients With IBD and CDI Fecal Microbiota Transplantation - Inflammatory Bowel Diseases, Clostridium Difficile Infection	Phase 1 / Phase 2	Completed	Brigham and Women's Hospital	50	2017-08-01	2021-02-10
Comparison of Cadazolid Versus Vancomycin in Children With Clostridium Difficile-associated Diarrhea (CDAD) Cadazolid, Vancomycin capsule, Vancomycin solution - Clostridium Difficile Infection	Phase 2 / Phase 3	Terminated	Actelion	1	2017-04-14	2025-07-08
Fecal Microbiota Therapy for Recurrent Clostridium Difficile Infection Fecal Microbiota, vancomycin, Loperamide - Clostridium Difficile Infection	Phase 2 / Phase 3	Unknown	Queen Elizabeth II Health Sciences Centre	50	2016-12-01	2016-09-27
Prevention of Clostridium Difficile-associated Diarrhea by Daily Intake of Kefir kefir - Clostridium Difficile Infection, Diarrhea	Phase 2	Terminated	St. Luke's Hospital of Duluth	2	2015-11-01	2022-05-19
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection RBX2660, Standard of Care Antibiotics - Clostridium Difficile Infection	Phase 2	Completed	Rebiotix Inc.	272	2015-10-01	2021-03-26
Gut Microbiota Changes After Fecal Microbiota Transplantation Fecal Microbiota Transplantation - Clostridium Difficile Infection	Phase 2	Unknown	The Miriam Hospital	6	2015-06-01	2015-09-23

Showing 20 of 33. Sign in to see all of them.

Narrower conditions

Clostridium Infections (33)  ·  Diarrhea (10)  ·  Enterocolitis, Pseudomembranous (4)  ·  Bacterial Infections (2)  ·  Inflammatory Bowel Diseases (2)  ·  Colitis (1)  ·  Colitis, Ulcerative (1)  ·  Colonic Diseases (1)  ·  Communicable Diseases (1)  ·  Crohn Disease (1)  ·  Diabetes Insipidus, Neurogenic (1)  ·  Digestive System Diseases (1)  ·  Dysbiosis (1)  ·  Enterocolitis (1)  ·  Gastroenteritis (1)

Broader conditions

Bacterial Infections and Mycoses (33)  ·  Infections (33)  ·  Gram-Positive Bacterial Infections (32)  ·  Bacterial Infections (31)  ·  Pathological Conditions, Signs and Symptoms (11)  ·  Signs and Symptoms (10)  ·  Signs and Symptoms, Digestive (9)  ·  Digestive System Diseases (5)  ·  Gastroenteritis (5)  ·  Gastrointestinal Diseases (5)  ·  Intestinal Diseases (5)  ·  Enterocolitis (3)  ·  Pathologic Processes (3)  ·  Disease Attributes (2)  ·  Colitis (1)

Interventions

Vancomycin (10)  ·  Fecal Microbiota Transplantation (8)  ·  Saline Solution (3)  ·  Adjuvants, Pharmaceutic (2)  ·  Metronidazole (2)  ·  alanylglutamine (2)  ·  cadazolid (2)  ·  ridinilazole (2)  ·  Anti-Bacterial Agents (1)  ·  Anti-Infective Agents (1)  ·  CB-183,315 (1)  ·  Fidaxomicin (1)  ·  Glutamine (1)  ·  Ibezapolstat (1)  ·  Kefir (1)

Sponsors

Sanofi Pasteur, a Sanofi Company (3)  ·  University of Wisconsin, Madison (3)  ·  Actelion (2)  ·  Brigham and Women's Hospital (2)  ·  Summit Therapeutics (2)  ·  University of Virginia (2)  ·  Acurx Pharmaceuticals Inc. (1)  ·  Boston Medical Center (1)  ·  Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1)  ·  Endeavor Health (1)  ·  Finch Research and Development LLC. (1)  ·  Immuron Ltd. (1)  ·  MGB Biopharma Limited (1)  ·  McMaster University (1)  ·  Medical College of Wisconsin (1)

Countries

United States (25)  ·  Canada (10)  ·  United Kingdom (3)  ·  Belgium (2)  ·  Czechia (2)  ·  Germany (2)  ·  Italy (2)  ·  Spain (2)  ·  Hungary (1)  ·  Israel (1)  ·  Japan (1)  ·  Norway (1)  ·  Poland (1)  ·  Romania (1)  ·  Sweden (1)

Top investigators

Nasia Safdar, MD PhD (2)  ·  Aasma Shaukat, MD MPH (1)  ·  Arnab Ray, MD (1)  ·  Becky Smith, MD (1)  ·  Christine Lee, MD (1)  ·  Cirle A. Warren, M.D. (1)  ·  Colleen Kelly, MD (1)  ·  Darrell Pardi, MD (1)  ·  Dimitri M Drekonja, MD (1)  ·  Ian R Davis, MD,FRCPC (1)  ·  Jennifer Grant, MD (1)  ·  Jerry Kanellos (1)  ·  Jessica R Allegretti, MD, MPH (1)  ·  Johan S Bakken, M.D., Ph.D. (1)

Results publications

PMID 25942722, PMID 26248357, PMID 26348734, PMID 26433782, PMID 26757463, PMID 27013431, PMID 27432604, PMID 27707993, PMID 27943501, PMID 28461207, PMID 29116880, PMID 29718329, PMID 31537446, PMID 34154439, PMID 35134880, PMID 35279084, PMID 37060545, PMID 37474181, PMID 39006315, PMID 39271107, PMID 40516571, PMID 40601321, PMID 41245385, PMID 42286373

NIH funding

2015 (2), 2008 (1)